Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) PT at $15.00

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $15.00.

A number of equities analysts have recently commented on EPRX shares. William Blair initiated coverage on Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They issued an “outperform” rating for the company. Zacks Research lowered Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald boosted their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in EPRX. Royal Bank of Canada raised its position in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after buying an additional 16,017 shares during the period. Quadrature Capital Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the second quarter valued at approximately $61,000. Bank of America Corp DE grew its stake in shares of Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares during the last quarter. Finally, TCI Wealth Advisors Inc. purchased a new stake in shares of Eupraxia Pharmaceuticals in the third quarter worth approximately $65,000.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $7.17 on Tuesday. The company’s fifty day moving average is $7.96 and its 200 day moving average is $7.00. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $9.32. The stock has a market capitalization of $257.83 million, a PE ratio of -6.96 and a beta of 1.55.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21). As a group, research analysts forecast that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.